Trisolventis

Menu
Get in touch

About Us

Your Trusted Partner in Pharma Transformation

about the company

Interim Leadership That Drives Real Business Impact

When leadership gaps arise, speed and clarity matter. I step in to take fullresponsibility-stabilizing teams, aligning priorities, and delivering measurable results from day one. With proven experience in Specialty Care and Rare Diseases across the DACH region, I combine strategic direction with hands-on execution. Whether navigating critical phases such as launch, market access, or organizational transition, I ensure momentum is maintained and business objectives are achieved. Focused, accountable, and results-driven-interim leadership that makes a difference where it matters most.

Mission

To enable pharmaceutical and biotech companies to successfully build, launch, and grow their business in the DACH, region through hands-on leadership, clear strategy, and excellence in execution.

Vision

To be the trusted partner for life science companies who need experienced Interim Managment support or are entering and scaling in Europe. To be known for delivering clarity in complexity and driving sustainable commercial success.

Why Choose Us

Empowering Pharma Growth with Strategic Leadership

Ensure that your actions in Germany are done right. With my support, deep market understanding, strong local networks, and hands-on execution, you avoid costly mistakes and gain speed where it matters most. From strategy to implementation, the focus is on turning market entry into measurable commercial success.
Proven leadership experience in top pharmaceutical organizations
Strong track record in launching and scaling pharma businesses
Deep understanding of the DACH market landscape
Flexible, interim-based support tailored to your needs
Commitment to delivering tangible, measurable results

Accelerating Your Market Success

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book. It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially.
Contact Us Today

How we Support You

Greenfield Setup

Develop a profound understanding of your market. Build your commercial Sales & Marketing organization from scratch – roles, processes, KPIs, hiring plan.

Launch Readiness

Manage interfaces between Regulatory, Market Access, and Commercial and Legal. From regulatory approval to market entry. Wholesale & Distribution: Select the right wholesale structure, align service levels, ensure availability and cost efficiency

Market Access & Pricing

Act as an interface between the Headquarter team and local partners. Delegation Lead in the AMNOG hearings and the GKV-SV price negotiations

Network & Speed

Established partner network for HR, Access, Distribution, Pharmacovigilance, Regulatory, and Legal.

Re-Launch Support

Analysis of the current performance, identification of critical topics, and creation of a clear improvement plan. If requested, providing leadership to ensure fast and effective implementation.

Interim Leadership

Experienced Leadership Team member of several leading pharma organisations in Germany and Austria. Hands-on, results focused, and experienced in managing pharma and healthcare teams.

Reference Projects

Slide

As Head of Germany for SIFI S.p.A., I led the
company's operations and commercial strategy in
a highly specialized market environment. I was
responsible for building and guiding the local
organization, driving growth, and ensuring
successful market access and execution in
ophthalmology within the German healthcare

At Eli Lilly, I was engaged to review the
performance of a key product and assess both
strategy and team effectiveness. The analysis
identified significant untapped opportunities,
leading to a clear re-focus of sales and marketing
activities and a more targeted, performance
driven approach.

In a project with Vaccentis, I worked closely
with the CEO to assess the performance and
future potential of a subsidiary. Through a
structured evaluation and development of an
improvement plan, it became clear that there
was no sustainable business opportunity,
leading to the decision to close the entity.

previous arrow
next arrow